Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Attachment |
| Title | PubMed entry |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/30196106 |
| Accessed | 2019/05/22 - 11:38:46 |
| Date Added | 2019/05/22 - 09:38:46 |
| Date Modified | 2019/05/22 - 09:39:11 |
| Parent item | An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de